Drs S. Brotini and L. Guidi presented at a Parkinson’s congress in 2014, as abstract LBA 21, data to support the use of palmitoylethanolamide in Parkinson’s disease.
The objective of their pilot study was to evaluate the efficacy of palmitoylethanolamide (PEA) in patients with advanced Parkinson’s Disease (PD).
They pointed out that idiopathic Parkinson’s Disease is a neurodegenerative disorder, together with and probably due to neuroinflammatory processes.
Due to the neuroprotective activities of PEA seen in animal models of Parkinson’s disease, where chronic treatment with PEA protected against loss of tyrosine hydroxylase-positive neurons in the substantia nigra, as well as against toxin-induced microglial activation.
The authors treated thirty outpatients with advanced Parkinson’s disease, assessed according to UK Parkinson’s Disease Society Brain Bank criteria, and clinical evaluations were performed by MDS-UPDRS new version (July 1, 2008) and Hoehn & Yahr Scale.
Each patient was evaluated over a period of 12 months. Data were analyzed using a repeated measures analysis of variance (ANOVA).
At the end of the follow up period analysis showed a statistically significant improvement (P<0,0001) of all the parameters considered, motor- and non-motor symptoms. In particular, there was a significant reduction of dyskinesias and prolonged therapeutic effect of L-dopa therapy.
Conclusion was that palmitoylethanolamide might play a role in the pharmacological treatment of Parkinson’s disease, via modulation of the pathological interaction between the dopaminergic pathways and glia.